Based on the assumption that high dose INH could be effective against MTB strains with low-level INH resistance because of mutations in the inhA promotor at positions 8, 15 or 16 [33], WHO guidelines suggested the use of high dose INH in the treatment of MDR/XDR-TB patients [34]. Here, INHA is linked to tuberculosis.